ADVM Stock Price, Adverum Biotechnologies Quote, Chart

Market Summary

USD8.01-0.24

Delayed

-2.91%

ADVM Stock Price

View Fullscreen

ADVM RSI Chart

ADVM Valuation

Market Cap

166.3M

Price/Earnings (Trailing)

-1.47

Price/Sales (Trailing)

46.18

EV/EBITDA

-0.13

Price/Free Cashflow

-1.8

ADVM Price/Sales (Trailing)

ADVM Profitability

EBT Margin

-3166.42%

Return on Equity

-61.93%

Return on Assets

-42.15%

Free Cashflow Yield

-55.66%

ADVM Fundamentals

ADVM Revenue

Revenue (TTM)

3.6M

Rev. Growth (Yr)

-100%

ADVM Earnings

Earnings (TTM)

-112.9M

Earnings Growth (Yr)

14.69%

Earnings Growth (Qtr)

-4.52%

Breaking Down ADVM Revenue

Last 7 days

-13.9%

Last 30 days

-29.4%

Last 90 days

-60.5%

Trailing 12 Months

5.5%

How does ADVM drawdown profile look like?

ADVM Financial Health

Current Ratio

9.24

ADVM Investor Care

Shares Dilution (1Y)

106.38%

Diluted EPS (TTM)

-10.2

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	5.9M	5.2M	4.4M	3.6M
2022	0	0	0	6.7M
2021	3.6M	5.5M	6.5M	7.5M
2019	0	0	1.6M	2.6M
2018	7.5M	7.6M	7.9M	7.5M
2017	1.7M	1.8M	1.9M	1.8M
2016	2.4M	2.5M	1.9M	1.5M
2015	745.0K	813.0K	1.6M	2.3M
2014	210.0K	195.0K	369.0K	572.0K
2013	142.5K	255.0K	367.5K	480.0K
2012	0	0	0	30.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Adverum Biotechnologies Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 07, 2024	lupher, jr. mark l.	bought	175,500	1.35	130,000	-
Feb 07, 2024	scopa james paul	bought	135,000	1.35	100,000	-
Sep 15, 2023	seyedkazemi setareh	sold	-9,429	1.5206	-6,201	chief development officer
Jun 07, 2023	rubinstein linda m	bought	145,490	1.4549	100,000	chief financial officer
Mar 15, 2023	soparkar peter	sold	-10,442	0.7816	-13,360	chief operating officer
Mar 15, 2023	riley brigit	sold	-5,704	0.7816	-7,299	chief scientific officer
Mar 15, 2023	fischer laurent	sold	-32,232	0.7816	-41,239	ceo, president and director
Sep 19, 2022	beckman richard	sold	-4,569	1.0697	-4,272	chief medical officer
Sep 19, 2022	soparkar peter	sold	-14,232	1.0697	-13,305	see remarks section
Sep 19, 2022	seyedkazemi setareh	sold	-6,479	1.0696	-6,058	chief development officer

Which funds bought or sold ADVM recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	Laurion Capital Management LP	new	-	6,206,540	6,206,540	0.05%
May 15, 2024	ADAR1 Capital Management, LLC	new	-	39,592	39,592	0.01%
May 15, 2024	Frazier Life Sciences Management, L.P.	new	-	15,119,100	15,119,100	0.64%
May 15, 2024	DEUTSCHE BANK AG\	sold off	-100	-14.00	-	-%
May 15, 2024	DEUTSCHE BANK AG\	new	-	28.00	28.00	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	new	-	2,340,100	2,340,100	-%
May 15, 2024	BARCLAYS PLC	new	-	754,000	754,000	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-3,233,620	-	-%
May 15, 2024	MORGAN STANLEY	sold off	-100	-3,877,220	-	-%
May 15, 2024	MORGAN STANLEY	new	-	7,947,180	7,947,180	-%

Are Funds Buying or Selling ADVM?

Are funds buying ADVM calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ADVM

No. of Funds

Unveiling Adverum Biotechnologies Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 14, 2024	versant ventures iv, llc	2.4%	500,387	SC 13D/A
Apr 29, 2024	bml investment partners, l.p.	5.1%	1,051,000	SC 13G/A
Feb 22, 2024	logos global management lp	7.2%	1.5e+07	SC 13G
Feb 15, 2024	tcg crossover gp ii, llc	9.9%	20,763,572	SC 13G
Feb 14, 2024	vivo opportunity fund holdings, l.p.	7.2%	1.5e+07	SC 13G
Feb 14, 2024	commodore capital lp	9.9%	1e+07	SC 13G/A
Feb 14, 2024	venrock healthcare capital partners iii, l.p.	7.5%	15,564,213	SC 13G/A
Feb 13, 2024	bank of america corp /de/	4.4%	4,425,895	SC 13G/A
Feb 12, 2024	morgan stanley	5.1%	5,150,496	SC 13G/A
Feb 09, 2024	frazier life sciences public fund, l.p.	2.4%	5,003,125	SC 13G

Recent SEC filings of Adverum Biotechnologies Inc

View All Filings

Date Filed	Form Type	Document
May 14, 2024	SC 13D/A	13D - Major Acquisition
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
May 02, 2024	ARS	ARS
May 02, 2024	DEF 14A	DEF 14A
May 02, 2024	DEFA14A	DEFA14A
Apr 29, 2024	SC 13G/A	Major Ownership Report
Mar 29, 2024	EFFECT	EFFECT
Mar 27, 2024	CORRESP	CORRESP
Mar 26, 2024	UPLOAD	UPLOAD

Peers (Alternatives to Adverum Biotechnologies Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Adverum Biotechnologies Inc News

Latest updates

Adverum Biotechnologies Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2021Q4	2021Q3	2021Q2	2021Q1	2021Q1	2019Q4	2019Q3	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3	2017Q2	2017Q1
Revenue	-	-	-	-	-	3,600,000	1,800,000	-	-	-	7,500,000	5,083,333	2,666,667	250,000	70,000	833,000	493,000	6,146,000	461,000	463,000	463,000	462,000
Operating Expenses	2.6%	26,839,000	26,158,000	34,529,000	33,065,000	33,839,000	33,940,000	34,419,000	38,522,000	44,538,000	36,143,000	-	19,653,000	17,333,000	16,829,000	24,306,000	20,396,000	-	-	-	-	-
S&GA Expenses	-100.0%	-	10,880,000	13,789,000	12,466,000	12,780,000	11,741,000	11,895,000	14,453,000	21,930,000	16,163,000	-	8,279,000	7,389,000	5,187,000	4,826,000	9,179,000	5,368,000	-	-	-	-
R&D Expenses	0.9%	15,410,000	15,278,000	20,740,000	20,599,000	21,059,000	22,199,000	22,524,000	24,069,000	22,608,000	19,980,000	-	11,374,000	9,944,000	11,642,000	14,480,000	11,217,000	-	-	-	-	-
EBITDA Margin	3.2%	-30.26	-31.28	-27.34	-24.56	-23.38	-22.01	-18.78	-17.16	-20.14	-24.41	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	100.0%	-	-1,133,000	17,000	21,000	17,000	19,000	-	-	-	-	-	-	-	-	-1,300,000	-	-	-	-	-	-
Earnings Before Taxes	0.2%	-24,787,000	-24,847,000	-32,868,000	-31,489,000	-29,039,000	-32,717,000	-34,409,000	-38,362,000	-44,333,000	-28,436,000	-	-18,925,000	-16,118,000	-15,659,000	-22,208,000	-	-	-14,789,000	-13,829,000	-	-
EBT Margin	3.6%	-31.66	-32.85	-28.79	-25.84	-24.51	-22.99	-19.41	-17.84	-20.98	-25.45	-	-	-	-	-	-	-	-	-	-	-
Net Income	-4.5%	-24,787,000	-23,714,000	-32,885,000	-31,510,000	-29,056,000	-32,736,000	-34,409,000	-38,362,000	-44,333,000	-28,436,000	-	-18,925,000	-16,118,000	-15,659,000	-20,958,000	-18,810,000	-	-	-	-	-
Net Income Margin	3.6%	-31.36	-32.55	-28.81	-25.86	-24.53	-23.00	-19.41	-22.80	-24.90	-26.91	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-8.4%	-23,335,000	-21,520,000	-24,408,000	-23,285,000	-22,497,000	-18,660,000	-30,167,000	-31,515,000	-37,563,000	-23,709,000	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	54.8%	268	173	197	241	276	308	332	375	407	440	491	526	462	483	508	331	349	223	206	210	221
Current Assets	93.8%	199	103	125	147	169	191	213	246	280	317	348	386	410	434	460	283	300	176	168	181	193
Cash Equivalents	102.1%	152	75.00	105	111	68.00	68.00	84.00	92.00	90.00	37.00	33.00	47.00	45.00	63.00	73.00	27.00	130	67.00	74.00	99.00	145
Net PPE	-6.8%	14.00	15.00	15.00	32.00	33.00	35.00	37.00	38.00	37.00	33.00	37.00	32.00	28.00	28.00	27.00	27.00	27.00	25.00	15.00	6.00	4.00
Liabilities	-4.5%	86.00	90.00	94.00	110	118	127	124	131	124	124	145	147	47.00	48.00	43.00	49.00	45.00	48.00	41.00	32.00	33.00
Current Liabilities	-13.5%	22.00	25.00	29.00	45.00	46.00	32.00	29.00	31.00	23.00	21.00	25.00	21.00	20.00	21.00	16.00	21.00	17.00	19.00	18.00	10.00	11.00
Shareholder's Equity	118.4%	182	83.00	103	131	158	182	208	244	283	316	346	379	415	434	465	283	304	175	164	178	188
Retained Earnings	-2.7%	-944	-919	-896	-863	-831	-802	-769	-729	-686	-648	-613	-575	-531	-502	-464	-437	-407	-385	-366	-349	-335
Additional Paid-In Capital	12.3%	1,127	1,004	999	995	990	986	980	976	970	965	960	955	946	937	930	720	713	561	531	528	524
Shares Outstanding	-100.0%	-	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	152	-	-	-	115	-	-	-	320	-	-	-	1,500	-	-	-	675	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-9.0%	-23,245	-21,328	-23,913	-23,249	-22,412	-18,475	-31,808	-28,879	-28,929	-25,815	-25,796	-33,915	-22,305	-22,224	-26,544	-16,907	-13,616	-14,835	-9,530	-11,588	-13,217
Share Based Compensation	0.4%	4,166	4,148	4,389	4,469	4,563	5,253	4,503	4,942	5,381	4,410	5,326	8,234	7,224	6,177	6,020	4,785	3,409	2,850	2,661	2,626	1,762
Cashflow From Investing	-123.0%	-22,027	-9,878	18,197	67,023	21,533	2,234	24,368	30,735	84,383	23,883	10,470	37,777	6,579	11,576	-132,373	-88,627	-70,743	-19,210	-15,016	-36,592	2,745
Cashflow From Financing	72116.9%	119,880	166	-105	8.00	-	242	-	362	3.00	375	-	517	1,505	376	204,254	2,731	148,624	26,771	-91.00	1,881	-370

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ADVM Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
License revenue	$ 0	$ 3,600
Operating expenses:
Research and development	15,410	21,059
General and administrative	11,429	12,780
Total operating expenses	26,839	33,839
Operating loss	(26,839)	(30,239)
Other income, net	2,052	1,200
Net loss before income taxes	(24,787)	(29,039)
Income tax provision	0	(17)
Net loss	(24,787)	(29,056)
Other comprehensive loss:
Net unrealized (loss) gain on marketable securities	(41)	739
Foreign currency translation adjustment	(19)	(7)
Comprehensive loss	$ (24,847)	$ (28,324)
Net loss per share — basic (in USD per share)	$ (1.50)	$ (2.90)
Net loss per share — diluted (in USD per share)	$ (1.50)	$ (2.90)
Weighted-average common shares used to compute net loss per share - basic (in shares)	16,479	10,030
Weighted-average common shares used to compute net loss per share - diluted (in shares)	16,479	10,030

ADVM Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 149,608	$ 75,000
Short-term investments	43,720	21,526
Prepaid expenses and other current assets	5,802	6,247
Total current assets	199,130	102,773
Operating lease right-of-use assets	51,760	52,266
Property and equipment, net	13,766	14,764
Restricted cash	1,976	1,976
Deposit and other long-term assets	1,196	1,231
Total assets	267,828	173,010
Current liabilities:
Accounts payable	1,897	1,921
Accrued expenses and other current liabilities	9,160	12,584
Lease liability, current portion	10,492	10,409
Total current liabilities	21,549	24,914
Lease liability, net of current portion	63,991	64,627
Total liabilities	85,540	89,541
Stockholders’ equity:
Preferred stock	0	0
Common stock	2	1
Additional paid-in capital	1,127,383	1,003,718
Accumulated other comprehensive loss	(533)	(473)
Accumulated deficit	(944,564)	(919,777)
Total stockholders’ equity	182,288	83,469
Total liabilities and stockholders’ equity	$ 267,828	$ 173,010

About Adverum Biotechnologies Inc

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

CEO	Dr. Laurent Fischer
WEBSITE	https://adverum.com
INDUSTRY	Biotechnology
EMPLOYEES	123

Adverum Biotechnologies Inc Frequently Asked Questions

What is the ticker symbol for Adverum Biotechnologies Inc? What does ADVM stand for in stocks?

ADVM is the stock ticker symbol of Adverum Biotechnologies Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Adverum Biotechnologies Inc (ADVM)?

As of Fri May 17 2024, market cap of Adverum Biotechnologies Inc is 166.26 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ADVM stock?

You can check ADVM's fair value in chart for subscribers.

What is the fair value of ADVM stock?

You can check ADVM's fair value in chart for subscribers. The fair value of Adverum Biotechnologies Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Adverum Biotechnologies Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ADVM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Adverum Biotechnologies Inc a good stock to buy?

The fair value guage provides a quick view whether ADVM is over valued or under valued. Whether Adverum Biotechnologies Inc is cheap or expensive depends on the assumptions which impact Adverum Biotechnologies Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ADVM.

What is Adverum Biotechnologies Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, ADVM's PE ratio (Price to Earnings) is -1.47 and Price to Sales (PS) ratio is 46.18. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ADVM PE ratio will change depending on the future growth rate expectations of investors.